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Abstract
It is becoming evident that nutrients and metabolic intermediates derived from such nutrients regulate cellular function by activating a
number of cell-surface G-protein coupled receptors (GPCRs). Until now, members of the GPCR family have largely been considered as
the molecular targets that communicate cellular signals initiated by hormones and neurotransmitters. Recently, based on tissue expression
patterns of these receptors and the concept that they may elicit the production of a range of appetite- and hunger-regulating peptides, such
nutrient sensing GPCRs are attracting considerable attention due to their potential to modulate satiety, improve glucose homeostasis and
supress the production of various pro-inflammatory mediators. Despite the developing interests in these nutrients sensing GPCR both as
sensors of nutritional status, and targets for limiting the development of metabolic diseases, major challenges remain to exploit their poten-
tial for therapeutic purposes. Mostly, this is due to limited characterisation and validation of these receptors because of paucity of selective
and high-potency/affinity pharmacological agents to define the detailed function and regulation of these receptors. However, ongoing
clinical trials of agonists of free fatty acid receptor 1 suggest that this receptor and other receptors for free fatty acids may provide a
successful strategy for controlling hyperglycaemia and providing novel approaches to treat diabetes. Receptors responsive to free fatty
acid have been of particular interest, and some aspects of these are considered herein.
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G protein-coupled receptors (GPCRs), sometimes also called
7-transmembrane domain receptors, are the largest family of
cell-surface, signal-transducing polypeptides. As the molecular
targets for a vast range of water-soluble hormones and neuro-
transmitters, they regulate the physiology and function of
essentially all cells and tissues. Because of this, they have
also been, by far, the most effectively targeted group of
proteins for small-molecule therapeutic medicines designed
to modulate or mask pathophysiological manifestations of
diseases. Because of the high affinity of many peptides and
other hormones for their GPCRs, initial reports of the ability
of members of this family to be activated by relatively high
concentrations of various nutrients and metabolic intermedi-
ates were inferred to have limited physiological relevance.
Despite this, it is now widely accepted that molecules
including lactate, succinate and free fatty acids are the physio-
logical regulators of specific GPCRs and that as nutritional
sensors these receptors can also be targeted therapeutically
in areas including metabolic diseases.
Receptors for free fatty acids, FFA1–3
A group of three GPCRs three of which are encoded by
the genes of which are closely linked on chromosome 19 in
man, respond to free fatty acids of varying chain lengths.
FFA1
FFA1 (previously designated as GPR40)(1) is activated by both
saturated and unsaturated medium-chain (carbon chain length
8–12) and longer-chain (carbon chain length 14–22) fatty
acids. The activation of this receptor, which is expressed by
b-cells of the pancreas as well as other tissues, including
enteroendocrine cells of the gut(2), results in enhanced
glucose-dependent secretion of insulin(1). The contribution
of enteroendocrine cells to the function of FFA1 is likely to
be substantial as each of the L(3), I(4) and K(5) cells has been
reported to express this receptor. Based on such studies, a
number of preclinical and clinical development programmes
are exploring the therapeutic potential of agonists of this
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receptor. The most advanced programme has been carried out
for the synthetic ligand TAK-875 ([(3S)-6-({20,60-dimethyl-40-[3-
(methylsulphonyl)propoxy]biphe-nyl-3-yl}meth-oxy)-2,3-dihy-
dro-1-benzofuran-3-yl]acetic acid hemi-hydrate) (Fig. 1)(6,7),
which has shown a capacity to reduce the levels of
HbA(1c), a marker of improved glycaemic control, in diabetics
without a propensity to promote hypoglycaemic episodes
as it (similar to other FFA1 agonists) only stimulates insulin
secretion in a glucose-dependent manner. Moreover, at least
in humans, TAK-875 does not significantly alter the secretion
of glucagon(8). These studies have attracted useful commen-
taries and generally positive analyses(9,10), although questions
remain in terms of the sustainability of effects during long-term
treatment. Interestingly, although both the clinical candidate
FFA1 agonists TAK-875 and AMG-837 ((S)-3-(4-((40-(trifluoro-
methyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid) (Fig. 1),
similar to the free fatty acids, have carboxylate functions that
are anticipated to interact with the same pair of arginine residues
in FFA1 that have been shown to be integral for the binding and
function of the endogenous ligands(11,12), the situation appears
to be more complex now. Recently, Lin et al.(13) have shown
convincingly that not all FFA1 agonist ligands are equivalent
in this regard and some may bind in a different manner to the
free fatty acids. Furthermore, different synthetic FFA1 agonists
also vary markedly in efficacy (a measure of the maximal
effect that they are able to produce). Given this information,
it is possible that a difference in clinical effectiveness may
be observed between different ligands, although it is currently
impossible to predict a priori if a full agonist of FFA1 or a
ligand that binds in a distinct, allosteric manner might offer
advantages over a partial agonist such as AMG-837.
FFA2 and FFA3
Although also acting as receptors for free fatty acids, both FFA2
(previously designated as GPR43) and FFA3 (previously desig-
nated as GPR41)(1) selectively bind to and are activated by
the short chain fatty acids (SCFAs) (carbon chain length 1–6),
particularly acetate (C2), propionate (C3) and butyrate (C4).
These SCFAs also fulfil much of the nutritional requirements
of colonocytes. The SCFAs are generated predominantly in
the gut by microbial fermentation of non-digestible carbo-
hydrates. Importantly, from a nutritional perspective, different
non-digestible carbohydrates are fermented to produce signifi-
cantly different levels of C2, C3 and C4. The capacity of the
intestinal microflora to generate C3, for example, is defined
by the proportions and contributions of different bacterial
groups and species as these utilise at least three distinct meta-
bolic pathways to produce C3 as an end product. As alterations
in the makeup and extent of the microbiota are associated with
inflammation and gut health state(14–16), there is considerable
interest in both prebiotic and probiotic strategies to modulate
the population and hence the effectiveness of SCFA pro-
duction(14–16). As well as being expressed in the distal ileum
and colon, close to the site of SCFA production, FFA2 is well
expressed by a range of immune cells, including peripheral
blood leucocytes, neutrophils and eosinophils, as well as by
adipocytes(1). This expression pattern has also promoted inter-
est in targeting FFA2 as a means to modulate adiposity and to
restrict the development of chronic metabolic diseases by lim-
iting sustained, low-grade inflammation. Moreover, the antag-
onism of this receptor has been suggested as a means to limit
the infiltration of neutrophils into the gut and hence counter
inflammatory gut conditions such as Crohn’s disease and
ulcerative colitis. Despite this, mouse FFA2 ‘knockout’
models have provided contradictory evidence as to the likely
effectiveness of this approach(17,18), and further analysis is
clearly warranted and required. Although clinical development
of FFA2-selective ligands is currently at a very early stage, a
number of patents describing both FFA2-selective agonists
and FFA2-selective antagonists have appeared(19,20) and pre-
liminary data on the effects of FFA2 agonists on the promotion
of neutrophil chemotaxis(21) and regulation of glucose uptake
in adipocytes(19) have been reported. Moreover, the SCFA-
mediated release of glucagon-like peptide 1 from enteroendo-
crine cells appears to be mediated via FFA2(22).
Although also activated by the same group of SCFAs as FFA2
and with a broadly similar expression profile, FFA3 is less well
characterised than FFA2. Despite early work(23) suggesting that
it may provide a means to regulate leptin release, this receptor
does not appear to be attracting the same level of interest as a
therapeutic target as FFA2. To date, there have been no reports
of highly selective synthetic ligands of FFA3 that target the
same binding site as the SCFAs and, as such, understanding
of the detailed function of this receptor lags behind. Despite
this, the noted selectivity of a number of small carboxylic
acids for either FFA2 or FFA3(24) indicates that, as for FFA2,
it should be possible to identify selective, high-potency/affi-
nity ligands for FFA3. Interestingly, the markedly higher
potency of C2 to activate human FFA2 v. FFA3, which has
resulted in the use of acetate as a selective activator of
FFA2(22,25), is not preserved in the rat and mouse ortholo-
gues(26) (Fig. 2). These observations reflect differences in
the extent of ligand-independent constitutive activity(26) and
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Fig. 1. Structures of FFA1 receptor agonist ligands currently undergoing clinical trials. (a) TAK-875 ([(3S)-6-({20,60-dimethyl-40-[3-(methylsulphonyl)propoxy]biphe-
nyl-3-yl}meth-oxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hemi-hydrate) and (b) AMG-837 ((S)-3-(4-((40-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-
ynoic acid).
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clearly demonstrate that C2 cannot be used in the absence of
‘knockout’ or ‘knockdown’ approaches to implicate a specific
role for FFA2 in rodent-derived cell lines and tissues.
Additional questions related to how species orthologue vari-
ation might affect the function of SCFA receptors arose with
the observation that the relative activity of various SCFAs are
entirely different at bovine FFA2 than either human or
rodent orthologues of FFA2(27). In particular, the substantially
lower potency of C2 as an agonist for bovine FFA2 may reflect
underlying physiological differences, with high levels of C2
and the other SCFAs being produced in the rumen and
marked expression of the receptor detected in the rumen(28).
Together, these observations suggest significant species ortho-
logue variation in the pharmacology of the SCFA receptors
with regard to their endogenous ligands, which probably
will translate to some degree of species selectivity in the phar-
macology of synthetic ligands targeting these receptors. This,
in turn, may hinder further validation of these receptors as
therapeutic targets.
Other G protein-coupled receptors activated by free
fatty acid
GPR84
Although recognised as a receptor responsive to medium-chain
saturated free fatty acid(29), GPR84 remains, by far, the least
studied and understood of the currently described receptors
for free fatty acid. Expressed predominantly by various
immune cells(29), interest in GPR84 has recently increased
due to studies in which co-culture of model macrophages and
adipocytes has been found to result in marked up-regulation
of GPR84 expression by the adipocytes(30). As there is consider-
able interest in the contribution of infiltrating macrophages
to adipose tissue function, such regulation of GPR84 might be
a target to limit the effects of increased fat mass and adiposity
in metabolic and other co-morbid diseases, but detailed assess-
ment of this will not be possible without the development of
useful pharmacological regulators for this receptor.
GPR120
A second receptor activated by medium-chain and long-chain
free fatty acids is GPR120. GPR120 is sometimes described as a
receptor for the n-3 group of PUFAs(31,32) that are present in
good amounts in oily fish(33) and have clear health benefits
in areas ranging from cardiovascular function to inflammation.
However, it is clear that such PUFAs have a wide range of
other molecular targets, including FFA1, and that other, less-
health-beneficial fatty acids can also activate this receptor.
Despite these issues, a number of observations have suggested
that the activation of GPR120 could have therapeutic benefits.
Key among these are reports that GPR120 may have a specific
capacity to mediate the action of long-chain fatty acids in
promoting the secretion of the incretin glucagon-like peptide 1
from enteroendocrine cells of the gut(34) and indications that the
activation of GPR120 produces extensive anti-inflammatory and
resulting insulin-sensitising effects(31). Specifically, the activation
of GPR120 has been reported to suppress the release of
pro-inflammatory cytokines from macrophages, which, given
the importance of inflammation in obesity-related insulin resist-
ance, has led to the speculation that the activation of GPR120
may therapeutically improve insulin resistance(34). Although
potentially of great importance, the studies demonstrating
these effects of GPR120 activation have been based on the
use of non-selective or poorly selective fatty acids or synthetic
ligands as agonists. Hence, although supported in part by
mRNA knockdown and/or knockout studies, these require
replication using highly selective pharmacological ligands
before GPR120 can be truly validated as a viable therapeutic
target. Furthermore, the pattern of expression of GPR120 in
enteroendocrine cells appears to be similar to that of FFA1
with at least L(3) and K(5) cells being shown to co-express the
two receptors. This further highlights the need for highly selec-
tive ligands to probe the function of GPR120. Although a
number of patents(35,36) describing GPR120-selective ligands
have been described, only recently has a series of potent and
specific ligands for GPR120 been described in the primary
literature(37). Hopefully, these and other ligands will now
allow such ideas to be re-examined.
A recent pair of publications has provided further physio-
logical and potential genetic support to favour agonism of
GPR120 as a potential therapy in diabetes. In the studies
carried out by Taneera et al.(38), the GPR120 receptor gene
(FFAR4 ) was identified as a gene strongly associated with dia-
betes and FFAR4 mRNA levels were reported to be substan-
tially lower in islets isolated from cadavers of diabetics than
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Fig. 2. Differing potencies of SCFAs at human FFA2 and FFA3. The responses to C2 (acetate, ), C3 (propionate, ) and C4 (butyrate, ) at FFA2 (a) or FFA3 (b)
are plotted as the percentage of maximal ligand response as measured in HEK-293 cells using an extracellular signal-regulated kinase 1/2 phosphorylation assay.
At FFA2, C2 and C3 are equipotent, while C4 displays lower potency. In contrast, C3 and C4 have similar potency at FFA3, while lower potency is observed for C2.
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in those from non-diabetic controls. Moreover, the studies car-
ried out by Ichimura et al.(39) identified a non-synonomous
SNP (Arg270His) in the open reading frame of human FFAR4
that was linked to obesity in a European population. In vitro
assays have indicated that this polymorphism results in virtual
abolition of receptor-mediated elevation of intracellular Ca2þ
levels(39). However, a number of caveats must be noted
about these studies. Humans are apparently the only higher
species in which an additional, longer, isoform of the
GPR120 receptor has been described alongside the short iso-
form that is found in both humans and other species(40). More-
over, careful in vitro studies have shown the major allele of the
long isoform to be unable to mediate the elevation of Ca2þ
levels(41). As the Arg270His position reported for the poly-
morphic variant indicates that it must have been the long iso-
form that was employed in these studies (the polymorphism
would correspond to Arg254His in the shorter isoform), it is
unclear as to how the minor allele SNP could result in the abla-
tion of a function that is reportedly already lacking for the
major allele. This discrepancy may simply reflect a sequence
position reporting error, but clearly requires further and
additional verification. Despite such concerns, the current
body of evidence suggests many positive and mutually reinfor-
cing reasons to promote GPR120 as a promising therapeutic
target. The potential capacity to regulate glucagon-like
peptide 1 secretion in the gut, to promote insulin release, prob-
ably via paracrine effects, from the pancreas and to constrain
adiposity and reduce insulin resistance via anti-inflammatory
mechanisms is favourable. Although recent efforts in medicinal
chemistry have been focused on improving the selectivity of
ligands between FFA1 and GPR120(37), there is also a strong
argument to be made that combined FFA1/GPR120 agonists
might display greater anti-diabetic efficacy than targeting
either receptor selectively. This, however, remains to be tested.
Conclusions
GPCR responsive to longer-chain free fatty acid function as
nutrient sensors for this important group of ligands. Because
of this, they are being explored as therapeutic targets to regu-
late metabolic diseases. Furthermore, growing recognition of
the ability of the gut microbiota to influence health via the
production of SCFAs as a consequence of the fermentation of
non-digestible carbohydrate has led to further attention being
paid to the association between nutrition and the development
of long-term chronic disorders that are among the most urgent
to target therapeutically. Such appreciation is rapidly resulting
in a new focus on the interrelationship between nutrients, the
microbiota and long-term human health.
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